MARKET

CRIS

CRIS

Curis
NASDAQ
1.830
-0.100
-5.18%
After Hours: 1.780 -0.05 -2.73% 18:34 07/11 EDT
OPEN
1.930
PREV CLOSE
1.930
HIGH
2.014
LOW
1.700
VOLUME
701.74K
TURNOVER
--
52 WEEK HIGH
8.29
52 WEEK LOW
1.020
MARKET CAP
21.96M
P/E (TTM)
-0.2938
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CRIS last week (0630-0704)?
Weekly Report · 6d ago
Curis Announces $7M Securities Purchase Agreement
TipRanks · 07/02 12:57
Curis launches $7M direct and concurrent private placement
Seeking Alpha · 07/02 12:57
Curis Announces $7M Registered Direct Offering And Private Placement, Selling 1.54M Shares At $2.275 Each; The Combined Purchase Price For 1 Share And The Associated Common Warrant Is $2.275; Combined Purchase Price For 1 Pre-Funded Warrant And The Associated Common Warrant Is $2.265
Benzinga · 07/02 12:36
CURIS ANNOUNCES $7.0 MILLION REGISTERED DIRECT AND CONCURRENT PRIVATE PLACEMENT
Reuters · 07/02 12:32
Press Release: Curis Announces $7.0 Million Registered Direct and Concurrent Private Placement
Dow Jones · 07/02 12:32
Weekly Report: what happened at CRIS last week (0623-0627)?
Weekly Report · 06/30 12:06
Weekly Report: what happened at CRIS last week (0616-0620)?
Weekly Report · 06/23 11:56
More
About CRIS
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.

Webull offers Curis Inc stock information, including NASDAQ: CRIS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRIS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRIS stock methods without spending real money on the virtual paper trading platform.